Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 21, 2025
Daily News
October 21, 2025
- Taiho Secures Japan, Asian Rights to Arcus’ HIF-2α Inhibitor Casdatifan
October 21, 2025
- Santen Nabs Distribution Rights to Beovu, Lucentis in South Korea
October 21, 2025
- Chugai, Rani Therapeutics Strike Deal on Oral Antibody Drug
October 21, 2025
- Chugai to File Tecentriq for Adjuvant Bladder Cancer Use in 2026 after Positive Data
October 21, 2025
- Japan Approves Nonprescription Version of Morning-After Pill: ASKA
October 21, 2025
- LDP, Nippon Ishin to Form Coalition; OTC-Like Drug Copay Review Set for FY2025
October 21, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…